Related references
Note: Only part of the references are listed.The graft-versus-leukemia effect using matched unrelated donors is not superior to HLA-identical siblings for hematopoietic stem cell transplantation
Olle Ringden et al.
BLOOD (2009)
Minimal residual disease levels assessed by NPM1 mutation-specific RQ-PCR provide important prognostic information in AML
Susanne Schnittger et al.
BLOOD (2009)
Prognostic factor analysis of the survival of elderly patients with AML in the MRC AML11 and LRF AML14 trials
Keith Wheatley et al.
BRITISH JOURNAL OF HAEMATOLOGY (2009)
Reduced Intensity Conditioning Compared With Myeloablative Conditioning Using Unrelated Donor Transplants in Patients With Acute Myeloid Leukemia
Olle Ringden et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
High-Dose Daunorubicin in Older Patients with Acute Myeloid Leukemia
Bob Lowenberg et al.
NEW ENGLAND JOURNAL OF MEDICINE (2009)
Association between BMI-1 expression, acute graft-versus-host disease, and outcome following allogeneic stem cell transplantation from HLA-identical siblings in chronic myeloid leukemia
Mohamad Mohty et al.
BLOOD (2008)
Sustained remissions of high-risk acute myeloid leukemia and myelodysplastic syndrome after reduced-intensity conditioning allogeneic hematopoietic transplantation:: Chronic graft-versus-host disease is the strongest factor improving survival
David Valcarel et al.
JOURNAL OF CLINICAL ONCOLOGY (2008)
Relapse risk in patients with malignant diseases given allogeneic hematopoietic cell transplantation after nonmyeloablative conditioning
Christoph Kahl et al.
BLOOD (2007)
Impact of conditioning regimen intensity on outcome of allogeneic hematopoietic cell transplantation for advanced acute myelogenous leukemia and myelodyspiastic syndrome
Edwin P. Alyea et al.
BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION (2006)
Results of genoidentical hemopoietic stem cell transplantation with reduced intensity conditioning for acute myelocytic leukemia: Higher doses of stem cells infused benefit patients receiving transplants in second remission or beyond - The acute leukemia working party of the European Cooperative Group for Blood and Marrow Transplantation
Norbert-Claude Gorin et al.
JOURNAL OF CLINICAL ONCOLOGY (2006)
Allogeneic hematopoietic stem-cell transplantation in AML and MDS using myeloablative versus reduced-intensity conditioning: the role of dose intensity
A Shimoni et al.
LEUKEMIA (2006)
Treatment for acute myelogenous leukemia by low-dose, total-body, irradiation-based conditioning and hematopoietic cell transplantation from related and unrelated donors
U Hegenbart et al.
JOURNAL OF CLINICAL ONCOLOGY (2006)
Allogeneic stem-cell transplantation using a reduced-intensity conditioning regimen has the capacity to produce durable remissions and long-term disease-free survival in patients with high-risk acute myeloid leukemia and myelodysplasia
S Tauro et al.
JOURNAL OF CLINICAL ONCOLOGY (2005)
National Institutes of Health consensus development project on criteria for clinical trials in chronic graft-versus-host disease: I. Diagnosis and staging working group report
AH Filipovich et al.
BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION (2005)
Hematopoietic cell transplantation (HCT)-specific comorbidity index: a new tool for risk assessment before allogeneic HCT
ML Sorror et al.
BLOOD (2005)
Fludarabine, melphalan, and alemtuzumab conditioning in adults with standard-risk advanced acute myeloid leukemia and myelodysplastic syndrome
K van Besien et al.
JOURNAL OF CLINICAL ONCOLOGY (2005)
The role of reduced intensity conditioning allogeneic stem cell transplantation in patients with acute myeloid leukemia:: a donor vs no donor comparison
M Mohty et al.
LEUKEMIA (2005)
Hematopoietic cell transplantation from HLA-identical sibling donors after low-dose radiation-based conditioning for treatment of CML
FR Kerbauy et al.
LEUKEMIA (2005)
Ablative allogeneic hematopoietic cell transplantation in adults 60 years of age and older
H Wallen et al.
JOURNAL OF CLINICAL ONCOLOGY (2005)
HLA-matched unrelated donor hematopoietic cell transplantation after nonmyeloablative conditioning for patients with chronic myeloid leukemia
F Baron et al.
BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION (2005)
Prognostic index for adult patients with acute myeloid leukemia in first relapse
DA Breems et al.
JOURNAL OF CLINICAL ONCOLOGY (2005)
Nonablative versus reduced-intensity conditioning regimens in the treatment of acute myeloid leukemia and high-risk myelodysplastic syndrome: dose is relevant for long-term disease control after allogeneic hematopoietic stem cell transplantation
M de Lima et al.
BLOOD (2004)
Revised recommendations of the international working group for diagnosis, standardization of response criteria, treatment outcomes, and reporting standards for therapeutic trials in acute myeloid leukemia
BD Cheson et al.
JOURNAL OF CLINICAL ONCOLOGY (2003)
HLA-matched unrelated donor hematopoietic cell transplantation after nonmyeloablative conditioning for patients with hematologic malignancies
MB Maris et al.
BLOOD (2003)
Postgrafting immunosuppression with sirolimus and cyclosporine facilitates stable mixed hematopoietic chimerism in dogs given sublethal total body irradiation before marrow transplantation from DLA-identical littermates
WJ Hogan et al.
BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION (2003)
A 6-month versus a 12-month surveillance for hepatocellular carcinoma in 559 hemophiliacs infected with the hepatitis C virus
E Santagostino et al.
BLOOD (2003)
Reduced intensity conditioning for allogeneic hematopoietic stem cell transplantation in patients with acute myeloid leukemia:: disease status by marrow blasts is the strongest prognostic factor
HG Sayer et al.
BONE MARROW TRANSPLANTATION (2003)
Low-dose total body irradiation (TBI) and fludarabine followed by hematopoietic cell transplantation (HCT) from HLA-matched or mismatched unrelated donors and postgrafting immunosuppression with cyclosporine and mycophenolate mofetil (MNF) can induce durable complete chimerism and sustained remissions in patients with hematological diseases
D Niederwieser et al.
BLOOD (2003)
Allografting with nonmyeloablative conditioning following cytoreductive autografts for the treatment of patients with multiple myeloma
DG Maloney et al.
BLOOD (2003)
Share Paper
